BIRC5 and breast carcinoma: Furthermore, CTLs specific for this peptide were successfully induced in PBMCs from all 7 HLA-A24+ patients (100%) with breast cancers and exhibited cytotoxicity against HLA-A24+/survivin+ adenocarcinoma cells [17].